慢性肝病患者血清sICAM-1、ACTA水平及临床意义

探讨可溶性细胞间粘附分子-1（sICAM-1）、激活素A（ACTA）与慢性肝脏疾病的关系。采用酶联免疫吸附试验（ELISA）检测128例慢性肝炎（CHB）患者及20例健康对照组血清sICAM-1、ACTA含量，同时测定其肝功能相关指标并进行相关性分析。慢性肝病患者血清sICAM-1、ACTA水平明显高于对照组，差异性显著（P〈0．05或P〈0．01）。与TBil、AST、GLB呈正相关，与ALB呈负相关（P〈0．05或P〈0．01）。血清sICAM-1、ACTA与透明质酸（HA）呈显著正相关（P〈0．05），SICAM-1与ACTA也呈显著正相关（P〈0．05）。sICAM-1、ACTA与HA水平呈正相关，提示sICAM-1、ACTA可做为反映慢性肝病患者肝纤维化以及肝损伤程度的指标。

Study on clinical significance and serum levels of Sicam - 1 and ACTA in patients with chronic hepatic disease

To investigate the correlation between soluble intercellular adhesion molccule-1(sICAM-1),activin A(ACTA) and chronic liver diseases.The serum levels of sICAM-1 and ACTA were measured with ELISA in 128 cases with chronic hepatitis and 20 healthy controls.Liver function tests were also determined.All results were subjected to correlative analysis.The serum levels of sICAM-1 and ACTA in patients with chronic liver diseases were significantly higher than those incontrol group(P<0.05 or P<0.01).ACTA and sICAM-1 were positively correlated with AST and GLB.Inversely,and negatively related with ALB(P<0.05 or P<0.01).The serum ICAM-1 and ACTA were positively correlated with hyaluronic acid(HA)(P<0.05).And ICAM-1 was also positively correlated with ACTA.It shows that serum sICAM-1 and ACTA are good index to reflect the degree of liver damage and liver fibrosis in patients of chronic liver diseases.